Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison
Author:
- M. MartyMMM. Marty
- 1 June 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10, 28-33
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer, 2000
- Cardiotoxicity of doxorubicin and other anthracycline derivativesJournal of Nuclear Cardiology, 2000
- Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast CancerCurrent Pharmaceutical Design, 2000
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.Journal of Clinical Oncology, 1998
- The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicinAnnals of Oncology, 1998
- Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.Journal of Clinical Oncology, 1998
- Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.Journal of Clinical Oncology, 1997
- Liposomal DoxorubicinJournal of Drug Targeting, 1996
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979